Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge

Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.

RTTNews | Pred 415 dňami

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.

RTTNews | Pred 425 dňami

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

RTTNews | Pred 572 dňami

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.

RTTNews | Pred 1153 dňami

Higher Open Called For Japan Stock Market

The Japan stock market bounced higher again on Wednesday, one session after ending the two-day winning streak in which it had advanced almost 200 points or 0.5 percent. The Nikkei 225 now rests just above the 42,520-point plateau and it's expected to open to the upside again on Thursday.

RTTNews | Pred 11 minútami

KOSPI May Reclaim 3,200-Point Level

The South Korea stock market bounced higher again on Wednesday, one day after ending the three-day winning streak in which it had improved almost 80 points or 2.6 percent. The KOSPI now sits just shy of the 3,190-point plateau and it may tick higher again on Thursday.

RTTNews | Pred 26 minútami

Korea Interest Rate Decision Due On Thursday

The Bank of Korea will wrap up its monetary policy meeting this morning and then announce its decision on interest rates, highlighting a light day for Asia-Pacific economic activity. The BoK is expected to keep its benchmark lending rate unchanged at 2.50 percent.

RTTNews | Pred 1 h 26 min

Swiss Franc Advances Against Majors

The Swiss franc climbed against its major counterparts in the New York session on Wednesday.

RTTNews | Pred 2 h 54 min

EURUSD	1.16439	GBPUSD	1.34999	AUDUSD	0.65086
USDJPY	147.262	USDCAD	1.37836	USDCHF	0.80177